Breaking News

MorphoSys to Delist from Frankfurt Stock Exchange & NASDAQ Following Novartis Acquisition

Novartis intends to implement a merger squeeze-out of MorphoSys’ minority shareholders.

Author Image

By: Charlie Sternberg

Associate Editor

MorphoSys AG has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.   Novartis BidCo Germany AG also informed MorphoSys of its intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys’ minority shareholders.   In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters